Compare TAK & NDAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TAK | NDAQ |
|---|---|---|
| Founded | 1781 | 1971 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.8B | 54.9B |
| IPO Year | 2007 | 2001 |
| Metric | TAK | NDAQ |
|---|---|---|
| Price | $18.68 | $94.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 18 |
| Target Price | $21.96 | ★ $108.69 |
| AVG Volume (30 Days) | 2.2M | ★ 2.9M |
| Earning Date | 10-29-2026 | 10-22-2026 |
| Dividend Yield | ★ 2.63% | 1.32% |
| EPS Growth | N/A | ★ 60.10 |
| EPS | N/A | ★ 1.80 |
| Revenue | N/A | ★ $4,277,000,000.00 |
| Revenue This Year | $4.39 | $12.55 |
| Revenue Next Year | $1.93 | $8.42 |
| P/E Ratio | ★ $41.25 | $52.02 |
| Revenue Growth | N/A | ★ 7.87 |
| 52 Week Low | $12.99 | $76.55 |
| 52 Week High | $19.10 | $101.79 |
| Indicator | TAK | NDAQ |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 53.93 |
| Support Level | $17.90 | $93.19 |
| Resistance Level | $18.91 | $96.30 |
| Average True Range (ATR) | 0.24 | 1.76 |
| MACD | -0.01 | 0.23 |
| Stochastic Oscillator | 73.20 | 62.84 |
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.